Search the Newsreel

Satellos Q2 loss widens to $11.7M, EPS misses estimates

Satellos Bioscience reported a Q2 2026 net loss of $11.7 million, or $0.56 per share, missing analyst estimates due to significantly increased R&D spending on its Phase 2 DMD clinical trials. Despite the widening loss, the company's cash reserves rose to $61.8 million, providing …

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience Inc. announced its Q2 2026 financial results, reporting a strong cash position of $61.8 million and progress in its clinical trials for SAT-3247, a drug candidate for Duchenne muscular dystrophy (DMD). The company highlighted favorable safety data from the TRAILHEAD adult DMD …

Satellos reports stable strength in four-adult Duchenne study

Satellos reported its second quarter 2026 financial results, including a net loss of $11.7 million, and provided updates on its clinical progress for SAT-3247 in Duchenne muscular dystrophy (DMD). The company highlighted stable strength and reduced muscle fat in a Phase 2 adult DMD …

Satellos Bioscience (NASDAQ: MSLE) ramps Duchenne R&D and strengthens cash

Satellos Bioscience reported increased net losses in the first half of 2026 due to higher R&D and G&A expenses, driven by advancing its Duchenne muscular dystrophy (DMD) clinical programs, SAT-3247. Despite widening losses, the company significantly strengthened its cash position to $61.8 million through …

Satellos Bioscience (MSLE) sets up US$300M shelf to fund Duchenne drug

Satellos Bioscience Inc. (TSX:MSCL) Stock Declines as Biotech Risks and Funding Concerns Pressure Sentiment

Satellos Bioscience Inc. (TSX:MSCL) experienced a 4.52% stock decline due to investor caution surrounding clinical-stage biotechnology companies, which face inherent development and funding risks. The company, focused on regenerative medicine for muscle disorders, is valued based on its clinical progress, technology validation, and potential …

Satellos Bioscience Inc Revenue Breakdown – NEO:MSCL

This article provides a basic overview of Satellos Bioscience Inc. (NEO:MSCL) on TradingView, focusing on its financial data and market performance. It indicates that no trades have occurred, suggesting limited market activity or a market closure. The page structure points to a detailed financial …

Satellos Bioscience Inc. (TSX:MSCL) Faces Crucial Smallcap Tests

Canadian healthcare smallcap company Satellos Bioscience Inc. (TSX:MSCL) is under scrutiny as the earnings season continues to highlight the importance of operational performance and digital transformation in the healthcare sector. The article implies that Satellos Bioscience, along with other featured companies like dentalcorp Holdings …

Satellos Bioscience Ord Shs (MSLE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Satellos Bioscience Ord Shs (MSLE), providing a breakdown of major shareholders and institutional holdings. It lists the proportion of shares held by entities like Bloom Burton & Co. Inc., Franklin Advisers, Inc., and Empery Asset Management, L.P., …

Satellos Bioscience Inc Revenue Breakdown – LSX:A4211W

This page on TradingView provides financial information for Satellos Bioscience Inc (LSX:A4211W), including an overview of its financials, statements, statistics, dividends, earnings, and segments. It specifically focuses on revenue breakdown by source and country. The content is primarily a navigation hub to various financial …

Independent Director of Satellos Bioscience Picks Up 1.9% More Stock

Franklin Berger, an Independent Director at Satellos Bioscience Inc. (TSE:MSCL), recently bought CA$117k worth of stock, increasing his holdings by 1.9%. This adds to a larger previous purchase of CA$339k earlier in the year at a higher price, indicating continued confidence in the company. …

MSLE Q1 2026 Earnings: EPS Misses Estimates as Development‑Stage Company Advances Pipeline - Earnings Momentum Score

MSLE Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline - Revenue Growth Outlook

MSLE Q1 2026 Earnings: Narrower Net Loss Beats Estimates but Stock Slips - Revenue Beat Analysis

MSLE Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline - Profit Warning Alert

MSLE Q1 2026 Earnings: EPS Beats Expectations Despite No Revenue; Shares Decline - Adjusted Earnings Analysis

Satellos Bioscience Inc. (MSLE) Latest Stock News & Headlines